SCHEMBL1464024

SCHEMBL1464024

COC(=O)CCC(NC(=O)OCc1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.52
CTSL P07711 1/20 0.51
CTSS P25774 1/20 0.51
CYP3A4 P08684 5/20 0.51
CYP2C9 P11712 4/20 0.51
CYP2C19 P33261 4/20 0.51
ALDH1A1 P00352 4/20 0.51
TSHR P16473 4/20 0.51
CYP1A2 P05177 4/20 0.51
POLB P06746 1/20 0.51
CYP2D6 P10635 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
CASP1 P29466 2/20 0.49
CTRB1 P17538 2/20 0.48
LMNA P02545 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7387408 0.92 CASP1 (0.50) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL16201457 0.86 ATM (0.54) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL6958944 0.86 ATM (0.54) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL16201456 0.83 CTRB1 (0.52) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL1463350 0.83 CTRB1 (0.52) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL10976358 0.83 ALDH1A1 (0.47) ATMCTSLCTSSCYP3A4CYP2C9
SCHEMBL11053442 0.83 KYNU (0.59) CTSLCTSSALDH1A1CASP1TRPM8
SCHEMBL7087075 0.83 KYNU (0.59) CTSLCTSSALDH1A1CASP1TRPM8
SCHEMBL220498 0.83 FOLH1 (0.56) CTSLCTSSALDH1A1CASP1
SCHEMBL5970693 0.83 FOLH1 (0.56) CTSLCTSSALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871760-B2 [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators ROCHE PALO ALTO LLC (US) 2014-10-28 US disclosed
EP-2480545-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011033055-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS P2RX3, P2RX7, P2RX1 ATM 2010/4885CTSL 3772/4885CTSS 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.